Company news
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) news
Every Fulcrum Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 4
Fulcrum Therapeutics Completes $68.5 Million Private Placement
June 10, 2020
Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
May 21, 2020
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
May 13, 2020
Fulcrum Therapeutics to Present at the BofA Securities 2020 Health Care Conference
May 11, 2020
Fulcrum Therapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Wednesday, May 13, 2020 at 8:00 a.m. ET
May 7, 2020
Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease
April 13, 2020
Fulcrum Therapeutics Provides Business Update on Impact of COVID-19
April 2, 2020
Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
March 24, 2020
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2019 Financial Results
March 5, 2020
Fulcrum Therapeutics Joins in Effort to “Reframe Rare” to Commemorate Rare Disease Day 2020
February 28, 2020
Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
February 26, 2020
Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio
January 29, 2020
Fulcrum Therapeutics Appoints Katina Dorton to its Board of Directors
January 6, 2020
Fulcrum Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
November 14, 2019
Fulcrum Therapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
November 6, 2019
Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD
October 4, 2019
Fulcrum Therapeutics Announces Multiple Presentations of Losmapimod Data at World Muscle Society Meeting
October 1, 2019